PROGRAM OVERVIEW
The National Comprehensive Cancer
Network (NCCN) Clinical Practice Guidelines in
Oncology TM
consist of a comprehensive set of guidelines
detailing the sequential management decisions and
interventions for the malignancies that affect 95%
of all patients with cancer. Developed by faculty at
NCCN
Member
Institutions using an evidence-based,
consensus process the NCCN Guidelines Panels develop over 100
separate guidelines. The NCCN Guidelines are widely used
in both the academic and community setting in the
United States to define the standard for appropriate
oncology care. The proposed symposium will be an
in-depth analysis of the evidence and thought
processes that led to the development of the
specific recommendations in the NCCN guidelines. Topics
will include diagnosis, staging work-ups with
discussion of prognostic markers and the use of
various therapies for breast, lung, colorectal,
gastric, esophageal, and head and neck cancers. The format may include presentations
of case reports and audience feedback to highlight
applications of the guidelines in clinical practice.
The local/regional experts will present the
demographics of their patient populations and their
customary state of the art management in the same
disease types. Participants will be given the
opportunity to comment on the NCCN guidelines with their
developers and provide input for consideration in
developing their own.
Physicians predominantly representing
the region and examplified below will be invited to
attend, although other countries not on this list
will be represented:
• Afghanistan • Bahrain • Egypt • Ethiopia • Lebanon
• Jordan • India • Oman • Pakistan • Saudi Arabia •
Syria • Turkey • United Arab Emirates
|
20
February 2008 |
|
18.00 –
20.00 |
Welcome Reception and Dinner |
Sponsored by Merck
|
|
21
February 2008 |
|
08.00 –
08.05 |
Welcome and Introduction |
Mohammad Jahanzeb, MD
Jorgen Kristensen, MD |
|
08.05 –
08.30 |
Introduction and Overview of the NCCN |
Joan
McClure, MS |
|
08.30 –
08.45 |
The NCCN
Guidelines Development Process |
Joan
McClure, MS |
|
08.45 –
09.00 |
Regional
Discussion of Breast Cancer Treatment in a Middle East Country |
Ezzeldin Ibrahim, MD |
|
09.00 –
09.20 |
Clinical
Case #1 |
Marwan Ghosn, MD &
Panelists |
|
09.20 –
09.50 |
Overview NCCN Breast Cancer Guidelines |
William Gradishar, MD |
|
09.50 –
10.20 |
Break |
|
|
10.20 –
10.40 |
Honorable Chief Guests
Official Opening of the Meeting |
His
Excellency
Ahmed
Al Mazrouei, MD
Edward D. Miller, MD |
|
10.40 –
10.55 |
Regional
Discussion of Lung Cancer Treatment in a Middle East Country |
Nouri
Bennini, MD |
|
10.55 –
11.15 |
Clinical Case #2 |
Yaser
Abd El Kader, MD Panelists |
|
11.15 –
11.45 |
Overview
of the NCCN Lung Cancer Guidelines |
David
Ettinger, MD |
|
11.45 –
12.00 |
Regional Discussion of Head & Neck Cancer Treatment in a Middle
East Country |
Jack
Borders, MD |
|
12.00 –
12.20 |
Clinical
Case #3 |
Sandeep Samant, MD & Panelists |
|
12.20 –
12.50 |
Overview of NCCN Head and Neck Guidelines |
Arlene Forastiere, MD |
|
12.50 –
13.50 |
Lunch |
|
|
13.50 –
14.05 |
Regional
Discussion of Colorectal Cancer Treatment in a Middle East
Country |
Scott
Strong, MD |
|
14.05 –
14.25 |
Clinical
Case #4 |
Hassan Jaafar, MD & Panelists |
|
14.25 –
14.55 |
Overview
of NCCN Colorectal Cancer Guidelines |
Paul
Engstrom, MD |
|
14.55 –
15.10 |
Organizing an Academic Cancer Center in Developing Countries:
Lessons from Lahore |
Faisal Sultan, MD |
|
16.30 –
17.30 |
Targeting Breast Cancer with Small Molecules -
Beyond ErbB1 |
Sponsored by
GlaxoSmithKline |
|
17.30 - 21.00 |
Dinner |
Sponsored by
sanofi-aventis
|
|
18.00 –
20.00 |
Evolving Strategies
for the Management
of Breast Cancer |
Sponsored by
Novartis |
|
20.30 –
22.30 |
Advances in the Treatment of Renal Cell and Hepatocellular
Carcinoma
|
Sponsored by
Bayer |
|
22 February 2008 |
|
08.30 –
08.40 |
Welcome & Introduction
Summary of Day 1 |
Mohammad Jahanzeb, MD
Jorgen Kristensen, MD |
|
08.40 –
08.55 |
Regional
Discussion of HCC Cancer Treatment in a Middle East Country |
Nehal
Masood, MD |
|
08.55 –
09.15 |
Clinical
Case #5 |
Mazen Taha, MD & Panelists |
|
09.15 –
09.45 |
Overview
of NCCN HCC Cancer Guidelines |
Al
Benson, MD |
|
09.45 –
10.00 |
Regional
Discussion of Gastric Cancer Treatment in a Middle East Country |
Fikri
Icli, MD |
|
10.00 –
10.20 |
Clinical
Case #6 |
Frank
Branicki, MD & Panelists |
|
10.20 –
10.40 |
Break |
|
|
10.40 –
11.10 |
Overview
of NCCN Gastric Cancer Guidelines |
Jaffer Ajani, MD |
|
11.10 –
11.55 |
Panel
Discussion Oncology Practice Guidelines in the Middle East: Does
Consensus Exist? |
ALL |
|
11.55 –
12.10 |
Closing Remarks |
Mohammad Jahanzeb, MD
Jorgen Kristensen, MD |
|
15.00 –
17.00 |
mTOR Inhibitors –
Promising Agent in the
Treatment of Solid Tumors |
Sponsored by
Novartis |
|
18.00 - 20.00 |
Cancer Patients, Better Living |
Sponsored by
Janssen-Cilag
|
|
20.30 - 22.30 |
Gala Dinner at the Al Ain Golf Club
|
|
SPONSORED BY:
TRAVEL ARRANGEMENTS
Etihad Airways is offering attendees a 15% discount on published fares. Please visit
http://www.etihadairways.com or contact your local Etihad Airways office for more information. Discount code: AUH 524.
Click
here for Symposium Invitation
Printable Agenda
Program
Overview
Organized by HADD-Tawam Hospital in
affiliation with Johns Hopkins Medicine in
collaboration with the National Comprehensive Cancer
Network (NCCN)
and
prIME
Oncology
An authorized program of the NCCN
|
Registration
